Onset's SoloPath transseptal catheter:
This article was originally published in Clinica
Onset Medical has CE marked its SoloPath percutaneous transseptal access catheter for sale in Europe, and plans to market it in the EU and "select countries worldwide". The catheter uses the Irvine, California-based firm's controlled deployment technology (CDT) to allow surgeons to access the left atrium and pulmonary veins. The diameter of the catheter when it enters the body is around 50% of the size of conventional access devices, Onset claims, but once positioned, it can be expanded to maintain access to the treatment site, creating an internal diameter larger than conventional devices. SoloPath received US FDA 510(k) clearance in March 2007 (see Clinica No 1249, p 22).
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.